<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706429</url>
  </required_header>
  <id_info>
    <org_study_id>B00844</org_study_id>
    <secondary_id>2020-002242-17</secondary_id>
    <secondary_id>ISRCTN57145331</secondary_id>
    <secondary_id>NIHR127575</secondary_id>
    <nct_id>NCT04706429</nct_id>
  </id_info>
  <brief_title>The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy</brief_title>
  <acronym>TEMPEST</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase 2 Evaluation of the Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Univar BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Manchester University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study has been designed to test whether a drug called trientine dihydrochloride&#xD;
      (also called Cufence) reduces heart muscle thickening, improves exercise capacity, improves&#xD;
      heart function and reduces abnormal heart rhythms in patients with hypertrophic&#xD;
      cardiomyopathy (HCM). The study is also assessing how trientine works in HCM. Participants&#xD;
      will be prescribed either trientine or placebo, for a period of 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCM is the most common inherited cardiovascular disorder. It is characterised by left&#xD;
      ventricular (LV) myocardial hypertrophy and fibrosis. Patients can experience symptoms of&#xD;
      effort intolerance, progressive heart failure and abnormal heart rhythms. There are currently&#xD;
      no treatments that alter the natural history of HCM. Patients and the cardiovascular field&#xD;
      have identified a &quot;critical need&quot; for clinical studies of drug therapies that target HCM&#xD;
      pathophysiological mechanisms.&#xD;
&#xD;
      Trientine dihydrochloride is a copper-chelating agent licensed for Wilson disease, a genetic&#xD;
      disorder of copper excretion, in which patients exhibit a cardiac phenotype that mimics HCM.&#xD;
      Proof of concept has been established through an MRC-funded study to suggest that use of&#xD;
      trientine may also be beneficial in HCM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular mass indexed to body surface area (LVMi)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in LVMi (g/m2), measured using CMR, from baseline to week 52.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine copper excretion</measure>
    <time_frame>12 months</time_frame>
    <description>Cumulative urine copper excretion, measured using urinary copper, assessed from baseline to weeks 13, 26, 39 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>12 months</time_frame>
    <description>Change in exercise capacity, measured using cardiopulmonary exercise testing (CPET), assessed from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-sinus supraventricular heart beats, presence and amount of atrial fibrillation, number of ventricular-origin beats and presence and amount of non-sustained ventricular tachycardia</measure>
    <time_frame>12 months</time_frame>
    <description>Change in number of non-sinus supraventricular heart beats, presence and amount of atrial fibrillation, number of ventricular-origin beats and presence and amount of non-sustained ventricular tachycardia, in 24 hours, measured using ambulatory heart monitoring, assessed from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating high sensitivity troponin</measure>
    <time_frame>12 months</time_frame>
    <description>Change in circulating high sensitivity troponin, assessed from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV global longitudinal strain and strain rate, wall thickness, mass, volumes and ejection fraction (EF)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in LV global longitudinal strain and strain rate, wall thickness, mass, volumes and ejection fraction (EF) measured using CMR, assessed from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak left ventricular outflow</measure>
    <time_frame>12 months</time_frame>
    <description>Change in peak left ventricular outflow tract gradient, measured using CMR, assessed from baseline to week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial volume and function</measure>
    <time_frame>12 months</time_frame>
    <description>Change in atrial volume and function, measured using CMR, assessed from baseline to week 52.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>LV myocardial cellular mass</measure>
    <time_frame>12 months</time_frame>
    <description>Change in LV myocardial cellular mass, measured using CMR, from baseline to week 52.</description>
  </other_outcome>
  <other_outcome>
    <measure>LV myocardial extracellular mass</measure>
    <time_frame>12 months</time_frame>
    <description>Change in LV myocardial extracellular mass, measured using CMR, from baseline to week 52.</description>
  </other_outcome>
  <other_outcome>
    <measure>LV myocardial extracellular volume</measure>
    <time_frame>12 months</time_frame>
    <description>Change in LV myocardial extracellular volume, measured using CMR, from baseline to week 52.</description>
  </other_outcome>
  <other_outcome>
    <measure>LV late gadolinium enhancement</measure>
    <time_frame>12 months</time_frame>
    <description>Change in LV late gadolinium enhancement, measured using CMR, from baseline to week 52.</description>
  </other_outcome>
  <other_outcome>
    <measure>PCr/ATP ratio</measure>
    <time_frame>12 months</time_frame>
    <description>Change in PCr/ATP ratio, measured using 31P MRS (sub-group), from baseline to week 52.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Trientine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trientine dihydrochloride 1200 mg per day. This shall be taken orally as two Cufence 200mg hard capsules two times per day. The IMP will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo shall be taken orally as two capsules two times per day. This will be dispensed to participants every 13 weeks for the duration of the study period (52 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trientine</intervention_name>
    <description>Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.</description>
    <arm_group_label>Trientine</arm_group_label>
    <other_name>Cufence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent.&#xD;
&#xD;
          2. Age 18-70 inclusive.&#xD;
&#xD;
          3. Hypertrophic cardiomyopathy (HCM), as defined by the European Society of Cardiology&#xD;
             HCM guidelines as: &quot;a wall thickness ≥15 mm in one or more LV myocardial segments that&#xD;
             is not explained solely by loading conditions&quot;. The same definition is applied to&#xD;
             first-degree relatives of patients with HCM i.e. all participants are required to have&#xD;
             a LV wall thickness ≥15 mm. Wall thickness is as measured on the most recent&#xD;
             cardiovascular magnetic resonance (CMR) scan performed prior to the baseline visit. If&#xD;
             CMR has not been performed previously, wall thickness measurement should be taken from&#xD;
             the most recent echocardiogram performed prior to the baseline visit. (It is&#xD;
             recognised that in the European Society of Cardiology guidelines a clinical diagnosis&#xD;
             of HCM in first-degree relatives requires a wall thickness that is less than this&#xD;
             value, however ≥15 mm is applied here in order to ensure that all participants have an&#xD;
             unequivocal phenotype).&#xD;
&#xD;
          4. New York Heart Association class I, II or III at the most recent clinical assessment&#xD;
             performed prior to the baseline visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous or planned septal reduction therapy.&#xD;
&#xD;
          2. Previously documented myocardial infarction or severe coronary artery disease.&#xD;
&#xD;
          3. Uncontrolled hypertension, defined as a systolic blood pressure of &gt;180mmHg or a&#xD;
             diastolic blood pressure of &gt; 100mmHg at Visit 1.&#xD;
&#xD;
          4. Known LV EF &lt; 50%, as measured on the most recent CMR scan performed prior to the&#xD;
             baseline visit. If CMR has not been performed previously, the most recent&#xD;
             echocardiogram performed prior to the baseline visit should be used.&#xD;
&#xD;
          5. Previously documented persistent atrial fibrillation.&#xD;
&#xD;
          6. Anaemia, defined as haemoglobin being below the local site normal reference range, at&#xD;
             Visit 1.&#xD;
&#xD;
          7. Iron deficiency, defined as serum iron being below the local site normal reference&#xD;
             range, at Visit 1.&#xD;
&#xD;
          8. Copper deficiency, defined as serum copper being below the normal reference range, at&#xD;
             Visit 1.&#xD;
&#xD;
          9. Pacemaker or implantable cardioverter defibrillator.&#xD;
&#xD;
         10. Known severe valvular heart disease, as demonstrated on the most recent heart imaging&#xD;
             performed prior to the baseline visit.&#xD;
&#xD;
         11. Previously documented other cardiomyopathic cause of myocardial hypertrophy (e.g.&#xD;
             amyloidosis, Fabry disease, mitochondrial disease).&#xD;
&#xD;
         12. History of hypersensitivity to any of the components of the investigational medicinal&#xD;
             product (IMP).&#xD;
&#xD;
         13. Known contraindication to MRI scanning.&#xD;
&#xD;
         14. Pregnancy, lactation or planning pregnancy. Women of childbearing capacity are&#xD;
             required to have a negative serum pregnancy test before treatment, must agree to&#xD;
             pregnancy tests at study visits as defined in the Section 8 and must agree to maintain&#xD;
             highly effective contraception as defined in Section 8 during the study.&#xD;
&#xD;
         15. Any medical condition, which in the opinion of the Investigator, may place the patient&#xD;
             at higher risk from his/her participation in the study, or is likely to prevent the&#xD;
             patient from complying with the requirements of the study or completing the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Miller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester University NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carly Lawrence</last_name>
    <phone>00 44 (0) 151 794 9763</phone>
    <email>tempest@liverpool.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liverpool Heart and Chester Hospital NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Cooper</last_name>
      <email>Rob.Cooper@lhch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Robert Cooper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton and Harefield NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjay Prasad</last_name>
      <email>S.Prasad@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sanjay Prasad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Schmitt</last_name>
      <email>matthias.schmitt@mft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Matthias Schmitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masliza Mahmod</last_name>
      <email>masliza.mahmod@cardiov.ox.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Masliza Mahmod</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trientine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

